Xinli Shi | Tumor | Best Researcher Award

Posted on by Pencis

Ms. Xinli Shi | Tumor | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

SCOPUS ID

ORCID ID

🏥MS. XINLI SHI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Ms. Xinli Shi, a Chinese national, began her academic journey with a B.Sc. in Biochemistry from the Department of Bioengineering at Hebei University of Science and Technology (1996–2001). She deepened her expertise in immunological mechanisms with an M.Sc. in Medical Immunology (2003–2007) from Hebei Medical University, followed by a Ph.D. in Immunology (2011–2014) from the West China College of Basic Medicine and Forensic Medicine, Sichuan University—one of China’s top-tier medical schools.

🩺PROFESSIONAL ENDEAVORS

Prof. Shi’s academic career spans over two decades, reflecting progressive growth:

  • 2001–2013: She served at Hebei Medical University as a Teaching Assistant and then Lecturer, establishing foundational teaching experience.

  • 2013–2018: Appointed Associate Professor and Master’s Supervisor at the School of Basic Medicine, Hebei University of Chinese Medicine.

  • 2015–2017: Completed a Postdoctoral Fellowship at the Bethune International Peace Hospital, affiliated with the Third Military Medical University, focusing on advanced clinical research.

  • 2018–2023: Promoted to Professor and Doctoral Supervisor at Hebei University of Chinese Medicine.

  • 2023–Present: Serving as Professor and Doctoral/Master Supervisor at the Experimental Management Center, Shanxi University of Chinese Medicine.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR

Prof. Shi has made notable contributions in the field of tumor immunology, particularly within the tumor microenvironment, focusing on:

  • Autophagy

  • Drug Resistance

  • Restenosis

  • Inflammation-induced tumorigenesis

Her research explores how immune signaling and cellular stress responses shape tumor progression and therapeutic resistance, offering novel targets for immunomodulatory and chemotherapeutic interventions.

She has guided:

  • 3 Ph.D. students

  • 20+ M.D. students

  • Supervised postdoctoral fellows, actively fostering academic development and translational medicine research.

🌍IMPACT AND INFLUENCE

Prof. Shi’s work is highly regarded in both Western medicine and Traditional Chinese Medicine (TCM) circles. Her interdisciplinary approach integrates modern immunology with TCM principles, enabling translational applications in cancer and chronic disease therapy. She has been part of numerous provincial and national talent programs, contributing to science policy and medical education reform.

🏆RESEARCH GRANTS AND FUNDING

Prof. Shi has led 14 research projects, funded by prestigious national and provincial bodies. These include:

  • 2 National Natural Science Foundation of China (NSFC) grants (No. 81873112 & 82274315)

  • China Postdoctoral Science Foundation

  • Hebei Natural Science Foundation (multiple years)

  • Shanxi Science and Technology Department

  • Shanxi Provincial Administration of Traditional Chinese Medicine Innovation Team

🔹 Total grant portfolio spans over a decade, supporting basic, translational, and clinical research initiatives.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Prof. Shi’s career exemplifies academic excellence, clinical relevance, and mentorship. With growing involvement in Shanxi’s TCM innovation programs, she is positioned to pioneer integrative oncology in China—blending evidence-based traditional practices with cutting-edge immunotherapy research. Her future directions include:

  • Building innovation teams

  • Leading multi-center translational studies

  • Expanding doctoral and postdoctoral programs

  • Enhancing international collaborations in cancer research

🧬CONCLUSION

Prof. Xinli Shi stands at the confluence of biochemistry, medical immunology, and TCM oncology, with over 20 years of academic and clinical experience. Her dedication to tumor biology, immune modulation, and interdisciplinary research continues to shape the landscape of cancer therapeutics in China. As a mentor, scholar, and innovator, she contributes profoundly to the development of next-generation scientists and the advancement of personalized medicine.

📊🔬NOTABLE PUBLICATION:

RalB promotes lymph node metastasis in tongue squamous cell carcinoma

Authors: Y. Zhang, Yuman; Z. Liu, Zhihan; Y. Yang, Yanguang; L. Jia, Lifeng; X. Shi, Xinli
Journal: Genes and Genomics
Year: 2025

Human umbilical cord mesenchymal stem cells promoted tumor cell growth associated with increased interleukin-18 in hepatocellular carcinoma

Authors: Y. Yang, Yanguang; S. Li, Shenghao; Q. Peng, Qing; Y. Zhang, Yuman; X. Shi, Xinli
Journal: Molecular Biology Reports
Year: 2024

Recent advances in graphitic carbon nitride-based heterojunction for biomedical applications

Authors: R. Jia, Ruilong; C. He, Cheng’en; S. Wang, Shanshan; G. Liao, Guangfu; X. Shi, Xinli
Citations: 3

Zhichen Xu | Radiation Oncology | Best Researcher Award

Posted on by Pencis

Zhichen Xu | Radiation Oncology | Best Researcher Award

First Hospital of Quanzhou | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. ZHICHEN XU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Xu Zhichen, originally from Putian and a member of the Han ethnic group, embarked on his medical journey at Luzhou Medical College, where he earned his Bachelor’s degree in Clinical Neurology (2005–2010). Driven by a growing interest in cancer care, he pursued a Master’s degree in Radiation Oncology at Fujian Medical University (2010–2013). His postgraduate training, conducted at the Fujian Provincial Tumor Hospital, laid the foundation for his specialization in radiotherapy.

🩺PROFESSIONAL ENDEAVORS

After completing his academic training, Mr. Xu underwent standardized residency training at Quanzhou First Hospital (2013.9–2014.9). Since September 2014, he has been an integral part of the hospital’s Radiotherapy Department, where he applies advanced radiotherapeutic techniques in clinical oncology. In 2024, he achieved the Vice Senior Certification in Radiotherapy, a testament to his professional growth and clinical mastery over the past decade.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON RADIATION ONCOLOGY

Mr. Xu specializes in Radiation Oncology, with a particular emphasis on esophageal cancer, focusing on enhancing therapeutic efficacy and patient outcomes. His clinical efforts are complemented by a strong commitment to research in radiotherapy optimization, side effect mitigation, and individualized treatment approaches.

🌍IMPACT AND INFLUENCE

A rising leader in regional cancer care, Mr. Xu is a core member of the Youth Committee of the Fujian Radiation Oncology Society. His selection for the “Hundred Talent Program” at Quanzhou First Hospital underlines his value as a future-forward clinician contributing to institutional development and innovation in cancer treatment.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Mr. Xu Zhichen aims to deepen his impact through work on precision radiotherapy, multidisciplinary cancer management, and the integration of AI and imaging technologies in clinical decision-making. He is committed to mentoring young oncologists and fostering collaborative research within and beyond Quanzhou.

🧬CONCLUSION

Mr. Xu Zhichen exemplifies the ideal blend of clinical expertise, research acumen, and leadership potential in the field of Radiation Oncology. With a focus on esophageal cancer, he continues to shape the future of radiotherapy in Fujian Province while contributing meaningfully to national and international cancer care standards.

 

📊🔬NOTABLE PUBLICATION:

A dynamic nomogram for predicting abdominal lymph node recurrence in patients with esophageal carcinoma

Authors: Xu Zhichen, Su Baoan, Lin Mingqiang, Xu Qinghua, Qu Mengke
Journal: Scientific Reports
Year: 2025

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

Posted on by Pencis

Dong Zhu | Organ-Defined Cancers | Best Researcher Award

临沂大学 | China

AUTHOR PROFILE

SCOPUS ID

🏥MR. DONG ZHU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Born in May 1999 in Zaozhuang, Shandong Province, China, Mr. Zhu Dong displayed an early aptitude for analytical thinking and computing. He embarked on his academic journey at Linyi University, earning a Bachelor of Engineering in Computer Science and Technology (2020–2022). Recognized for his diligence and academic excellence, he was admitted into the university’s graduate program, where he is currently pursuing a Master of Engineering in Computer Technology (2022–2025).

🩺PROFESSIONAL ENDEAVORS

While still a graduate student, Mr. Zhu has already made substantial strides in the field of medical image processing. He has co-developed advanced deep learning frameworks tailored to complex clinical imaging tasks, such as 3D liver segmentation and breast tumor analysis. His participation in collaborative and interdisciplinary projects reflects a forward-looking and adaptable research mindset.

🔬CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Zhu’s primary research focus is on deep learning applications in medical image segmentation, with specific interests in:

  • 3D U-Net architectures
  • Attention mechanisms
  • Multi-scale feature fusion
  • Electrocardiogram (ECG) signal classification

🏆AWARDS AND HONOURS

  • National Scholarship, 2023–2024
  • First-Class Academic Scholarship, 2022–2023 & 2023–2024
  • Outstanding Communist Youth League Cadre, 2023–2024
  • Excellent Student Award, 2023–2024
  • Advanced Individual Award, 2023–2024

🌍IMPACT AND INFLUENCE

Though early in his career, Mr. Zhu’s models are contributing to more accurate, automated diagnosis systems in clinical imaging. His open-access publications and conference proceedings are cited in discussions around deep learning for medical applications, particularly in liver and breast imaging workflows. His interdisciplinary work is fostering stronger links between AI and clinical diagnostics.

🏆LEGACY AND FUTURE CONTRIBUTIONS

With a growing portfolio of first-author publications, Mr. Zhu is establishing himself as a rising researcher in AI-driven medical imaging. His focus on practical, clinically relevant problems positions him to contribute significantly to next-generation diagnostic technologies. In the coming years, he aims to expand his research to include multimodal imaging analysis, federated learning, and real-time diagnostic systems for point-of-care settings.

🧬CONCLUSION

Mr. Zhu Dong represents a new wave of interdisciplinary researchers who blend deep learning techniques with clinical needs. His trajectory reflects not only strong technical skills but also a deep commitment to improving healthcare through innovation. With continued support, mentorship, and exposure to global research networks, he is well-poised to lead breakthroughs in intelligent medical diagnostics.

 

📊🔬NOTABLE PUBLICATION:

3DMAU-Net: Liver Segmentation Network Based on 3D U-Net

Authors: Zhu, Dong; Ma, Tianyi; Yang, Mengzhu; Hu, Shunbo; Wang, Yongfang
Journal: Optoelectronics Letters
Year: 2025

Haixin Liang | Oncology Nursing | Best Researcher Award

Posted on by Pencis

Ms. Haixin Liang | Oncology Nursing | Best Researcher Award

Sichuan Cancer Hospital | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Born in April 1987 in China, Haixin Liang embarked on her journey in healthcare with a deep commitment to service and academic excellence. She earned her Master’s degree in Nursing, laying the foundation for a focused career in oncology nursing. Her early academic training fostered a keen interest in clinical innovation, evidence-based care, and nursing education.

🏆 PROFESSIONAL ENDEAVORS

Since July 2012, Liang has served at Sichuan Cancer Hospital, one of China’s leading institutions in cancer treatment and research. Currently holding the position of Nurse Supervisor and Oncology Advanced Practice Nurse, she plays a pivotal role in patient care management, nursing staff training, and clinical innovation. Liang’s responsibilities span clinical supervision, implementation of best nursing practices, and mentoring student nurses.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY NURSING

Haixin Liang’s professional contributions are deeply rooted in the nursing care of oncology patients, particularly focusing on:

  • Radiation-induced complications

  • Patient-centered safety practices

  • Clinical device innovations for cancer care

Her research often emphasizes the quality of life of nasopharyngeal carcinoma patients, symptom management, and infection control.

🌍 IMPACT AND INFLUENCE

Liang’s innovations and scholarly work have had a direct impact on clinical practice, particularly in:

  • Infection control through safe disposal of medical sharps

  • Improved nursing techniques in managing radiation-induced complications

  • Enhancing communication and understanding between caregivers and patients

Her educational leadership has influenced the next generation of oncology nurses, while her research is integrated into hospital protocols and academic curricula.

.

📖 ACADEMIC CITATIONS AND RECOGNITION

While specific citation data is not provided here, her frequent first-author contributions in core Chinese nursing journals suggest substantial academic recognition and relevance in the field of clinical nursing innovation, especially among oncology nursing practitioners in China.

🔮RESEARCH GRANTS AND FUNDING

Liang’s device innovations have led to two awarded patents, indicating support for clinical translation of nursing tools:

  • 🧪 Portable Sharps Disposal Container
    Patent Number: ZL 2014 20067555.3 – Issued: 2014.08.06

  • 🧪 Nasogastric Tube Injection Device
    Patent Number: ZL 2020 22568964.X – Issued: 2020.11.09

Her work is further supported through institutional awards and case competitions, signifying recognition and potential for funding in applied clinical research.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Haixin Liang’s legacy lies in:

  • Bridging practical nursing with innovation

  • Leading in radiotherapy nursing care

  • Cultivating student and staff excellence in oncology nursing

Her future contributions are expected to include:

  • Development of more patient-friendly clinical devices

  • Publishing guidelines for managing radiotherapy side effects

  • Expanding evidence-based nursing frameworks in oncology

🌍CONCLUSION 

Haixin Liang exemplifies a nurse leader who transcends bedside care through innovation, research, and mentorship. With a focused commitment to oncology nursing, her work continues to shape clinical practices and empower nursing professionals across China. Her profile is a testament to how clinical insight, scholarly pursuit, and technological innovation can converge in nursing for maximum patient impact.

 

📊🔬NOTABLE PUBLICATION:

Correlation between changes of taste or smell and self-reported symptoms in patients with nasopharyngeal carcinoma received radiotherapy and chemotherapy

Authors: Haixin Liang (First Author)

Journal: Guangdong Medical Journal

Year: 2018

 

Hongyu li | Breast Cancer | Best Researcher Award

Posted on by Pencis

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS 

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER 

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE 

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION 

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

 

📊🔬NOTABLE PUBLICATION:

Title: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

Authors: Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Journal: Scientific Reports (Nature Publishing Group)

Year: 2025

Jianhua Luo | Cellular Immunotherapy | Women Researcher Award

Posted on by Pencis

Jianhua Luo | Cellular Immunotherapy | Women Researcher Award

National Key Laboratory of Immunity & Inflammation, Institute of Immunology | China

AUTHOR PROFILE

Scopus

🎓 EARLY ACADEMIC PURSUITS

Ms. Jianhua Luo began her scientific journey at China Pharmaceutical University, earning a Bachelor’s degree in Food Quality and Safety (2012–2016). She pursued further specialization with a Master’s degree in Microbiology and Biochemical Pharmacy (2016–2019) from the same institution. With a growing interest in immunological mechanisms in disease treatment, she earned her Ph.D. in Medical Immunology (2020–2023) from the Second Military Medical University of the Chinese People’s Liberation Army — one of China’s most respected institutions in biomedical sciences.

🏆 PROFESSIONAL ENDEAVORS

Ms. Luo has engaged in collaborative, interdisciplinary research with emphasis on tumor immunotherapy, especially through CAR-NK cell engineering. Her work integrates molecular immunology, bioinformatics, and genetic engineering, with a strong translational focus. She has contributed extensively to both laboratory innovation and preclinical development of cellular immunotherapies for solid tumors.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CELLULAR IMMUNOTHERAPY

Ms. Luo has emerged as a key contributor in the cellular immunotherapy space, focusing on CAR-NK cells enhanced with synthetic cytokines (like Neoleukin-2/15) to improve anti-tumor efficacy in solid cancers. Her work on signal conversion platforms, which translate inhibitory signals into activation cues, represents a novel mechanism to bypass the immunosuppressive tumor microenvironment. She has co-developed autocrine IL-2Rβγ agonist-armored CAR-NK cells, now patented in China. Moreover, her interest extends to PANoptosis, immune cell metabolism in elderly populations, and immune responses to transplantation injuries.

🌍 IMPACT AND INFLUENCE

Her research, published in high-impact journals such as Signal Transduction and Targeted Therapy, Pharmacological Research, and the Journal of Translational Medicine, has influenced the next-generation design of adoptive cell therapies. She is a co-first or co-corresponding author in multiple publications that introduce disruptive approaches in the field. Additionally, her patent contributions and involvement in software development for AI-assisted cell therapy analysis have extended her impact into digital health and precision oncology.

📖 ACADEMIC CITATIONS AND RECOGNITION

While a detailed citation count requires real-time database querying (e.g., Google Scholar or Scopus), her work appears in top-tier, peer-reviewed journals, suggesting she is accruing rapid academic citations, particularly around her publications on CAR-NK cells, tumor immune evasion, and chemo-immunotherapy synergy. Notably, her co-first author paper on Neoleukin-2/15-armored CAR-NK cells (2025) is expected to become a landmark citation in CAR-based immunotherapy research.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Ms. Luo’s patents, software copyrights, and published research point toward a legacy that bridges wet-lab biology and AI-powered immunotherapy solutions. Her tools for analyzing NK cell phenotypes and functions using machine learning and computer vision provide a strong base for future clinical translation and personalized immunotherapy. Her ongoing involvement in CAR-NK cell design, immune metabolism, and transplantation immunology positions her as a rising leader in precision immune-oncology.

🌍CONCLUSION 

Ms. Jianhua Luo represents a new generation of immunotherapy innovators—a multidisciplinary researcher who integrates molecular immunology, bioengineering, and computational tools to solve some of oncology’s most pressing challenges. With a robust publication record, recognized patents, software contributions, and involvement in national-level research programs, she is well-positioned to define the future landscape of cellular immunotherapy.

📊🔬NOTABLE PUBLICATION:

Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation

Journal: Signal Transduction and Targeted Therapy

Year: 2025

Citations: 1

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Posted on by Pencis

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024

Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015

Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016

A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015

Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Posted on by Pencis

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health | China

AUTHOR PROFILE

ORCID ID

SCOPUS

🎓 EARLY ACADEMIC PURSUITS

Dr. Wenhao Chen embarked on his medical journey at Peking University, where he completed his MD (2004–2012), laying a strong foundation in clinical and surgical sciences. His early exposure to academic rigor and translational research in one of China’s most prestigious institutions catalyzed his long-term interest in orthopedics and musculoskeletal oncology.

🏆 PROFESSIONAL ENDEAVORS

Currently serving as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine, Dr. Chen leads both clinical operations and scientific innovation. He completed his postdoctoral fellowship (2019–2020) at Massachusetts General Hospital (MGH), USA, a globally renowned center, where he honed his skills in translational and molecular orthopedics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON OSTEOSARCOMA

Dr. Chen’s core research focus centers on osteosarcoma, Ewing sarcoma, and bone regeneration mechanisms. His work spans from genomic risk modeling to machine learning applications in prognosis prediction. Notably:

  • Identification of LARS as an essential gene in osteosarcoma proliferation via CRISPR-Cas9 screens (J Transl Med, 2022).

  • Developed prognostic nomograms and glycolysis-based risk scores to stratify osteosarcoma survival (J Orthop Res, 2022; Medicine, 2019).

  • Investigated radiotherapy sensitivity and metastatic prediction in osteosarcoma (J Cancer Res Clin Oncol, 2023).

His integration of molecular biology, AI modeling, and clinical data science reflects a translational approach that bridges lab discoveries with bedside applications.

🌍 IMPACT AND INFLUENCE

Dr. Chen’s body of work demonstrates multidisciplinary impact:

  • Oncology (osteosarcoma, Ewing sarcoma)

  • Orthopedic surgery innovations

  • Inhalation therapy for pulmonary fibrosis (J Transl Med, 2024)

  • Neural regeneration using viral gene therapy (Brain Res Bull, 2017)

His collaborations with top U.S. institutions and international teams exemplify his global research footprint and scientific leadership.

📖 ACADEMIC CITATIONS AND RECOGNITION

With 17 peer-reviewed publications, many in high-impact journals such as FASEB Journal, Journal of Translational Medicine, and Journal of Orthopaedic Research, Dr. Chen has amassed significant citations in the fields of oncology, orthopedics, and translational medicine, reflecting the clinical utility and scientific merit of his contributions.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Chen’s vision for the future includes:

  • Developing non-invasive diagnostic models for early osteosarcoma detection

  • Expanding research into bone-tissue engineering and regeneration

  • Training future orthopedic surgeons and clinician-scientists with dual clinical and computational expertise

🌍CONCLUSION 

Dr. Wenhao Chen stands at the forefront of orthopedic science, blending clinical acumen, molecular insights, and computational power to reshape musculoskeletal disease treatment.

 

📊🔬NOTABLE PUBLICATION:

Title: The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma
Journal: Journal of Bone Oncology
Year: 2025

Title: Diminished GALNS activity in induced pluripotent stem cells of mucopolysaccharidosis IVA caused by compound p.S162Y and p.C165F mutation
Journal: QJM: An International Journal of Medicine
Year: 2025

Title: Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β/β‐catenin pathway
Journal: The FASEB Journal
Year: 2024

Title: Outcomes of two-stage double-level rotational osteotomy in treating patients with congenital proximal radioulnar synostosis
Journal: World Journal of Pediatric Surgery
Year: 2023

Title: A novel risk score model based on glycolysis‐related genes and a prognostic model for predicting overall survival of osteosarcoma patients
Journal: Journal of Orthopaedic Research
Year: 2022

Dr. CHUANQING Xu | Infectious Disease | Best Researcher Award

Posted on by Pencis

Dr. CHUANQING Xu | Infectious Disease | Best Researcher Award

Beijing University of Civil Engineeing and Architecture | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Professor Chuanqing Xu began his academic journey with a Bachelor of Science in Mathematics from Liaocheng University in 1995, where he laid a strong foundation in algebra, geometry, probability, and mathematical analysis. His pursuit of mathematical depth led him to obtain both Master’s and Doctoral degrees in Applied Mathematics from Beijing University of Technology, where his focus expanded to include nonlinear analysis, statistical modeling, and time series analysis—skills that would later prove pivotal in infectious disease modeling.

🏆 PROFESSIONAL ENDEAVORS

With over 14 years of academic experience at the Beijing University of Civil Engineering and Architecture, Professor Xu currently serves as a Professor of Mathematics. His teaching portfolio spans doctoral, postgraduate, and undergraduate levels, covering topics such as:

  • Advanced Mathematics, Linear Algebra, Probability and Statistics

  • Qualitative Theory of Differential Equations, Stability Theory, and

  • Generalized Functional Analysis.

Beyond the classroom, he is an active mentor and leader of a prominent research group focusing on infectious disease modeling and epidemic dynamics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON INFECTIOUS DISEASES

Professor Xu’s core research expertise lies in mathematical modeling and dynamic analysis of infectious diseases. Notable accomplishments include:

  • 📊 Modeling COVID-19 transmission dynamics to evaluate infection peaks, healthcare system demands, and containment measures.

  • 🏅 Assessing disease spread among athletes and volunteers during the 2022 Beijing Winter Olympics.

  • 🦠 Estimating the burden of Hepatitis B across China through epidemiological data analysis and predictive modeling.

These contributions have directly informed public health strategies and resource allocation.

🌍 IMPACT AND INFLUENCE

Through his work, Professor Xu has enhanced national readiness and resilience in the face of pandemics and viral outbreaks. His research bridges the gap between theoretical mathematics and practical healthcare applications, proving invaluable during critical times like the COVID-19 pandemic and large-scale events like the Winter Olympics.

📖 ACADEMIC CITATIONS AND RECOGNITION

Professor Xu has published 16 high-level peer-reviewed articles in esteemed journals, contributing significantly to the body of knowledge in applied mathematics and epidemiology. His works are widely cited, reflecting his role as a recognized authority in disease modeling.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Professor Xu continues to inspire a new generation of researchers, emphasizing the interdisciplinary power of mathematics in solving real-world problems. His lab is currently exploring machine learning and AI tools to enhance the accuracy and speed of infectious disease prediction models.

His research and innovations will undoubtedly shape the future of medicine, providing safe, effective, and scientifically backed treatments that integrate the wisdom of traditional Chinese medicine with modern scientific advancements.

🌍CONCLUSION 

As a visionary in mathematical epidemiology, Professor Chuanqing Xu envisions a future where real-time disease forecasting can guide swift public health decisions, save lives, and prepare societies for emerging global health threats. His dedication to precision, teaching, and innovation cements his legacy as a pioneer at the intersection of mathematics and medicine.

 

📊🔬NOTABLE PUBLICATION:

A Mathematical Model to Study the Potential Hepatitis B Virus Infections and Effects of Vaccination Strategies in China

Authors: Chuanqing Xu, Yu Wang, Kedeng Cheng, Xin Yang, Xiaojing Wang, Songbai Guo, Maoxing Liu, Xiaoling Liu

Journal: Vaccines

Year: 2023

Ping Xue | Biomedical Optics | Best Research Article Award

Posted on by Pencis

Prof. Ping Xue | Biomedical Optics | Best Research Article Award

Tsinghua University | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Ping Xue embarked on his academic journey in Applied Physics, earning his Bachelor of Science (B.S.) degree in 1988 from Tsinghua University, Beijing, P.R. China. Demonstrating a strong inclination toward the field of optics, he further pursued and successfully obtained his Ph.D. in Optics in 1993, also from Tsinghua University, laying a robust foundation for his future contributions in the realm of physics and optics.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Following the completion of his doctoral studies, Prof. Xue commenced his teaching and research career at Tsinghua University. He served as a Lecturer from 1993 to 1996, then as an Associate Professor from 1996 to 2000, and achieved the title of Full Professor of Physics in 2000, a position he continues to hold.

In addition to his academic roles, he has been actively engaged in international collaboration. From 2001 to 2002, Prof. Xue was a Visiting Scientist at the Research Laboratory of Electronics (RLE) at the prestigious Massachusetts Institute of Technology (MIT).

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMEDICAL OPTICS

Prof. Ping Xue has established himself as a pioneering figure in the interdisciplinary fields of:

  • Biomedical Imaging

  • Advanced Laser Technology

  • Laser Spectroscopy

  • Optical Informatics

His research has contributed significantly to the development and innovation of nano-optoelectronic systems, leveraging cutting-edge optical methods to explore and manipulate matter at molecular and atomic levels.

He has held pivotal leadership roles, including:

  • Deputy Director of the Key Laboratory of Atomic and Molecular Nanosciences, Ministry of Education (2002–2011)

  • Deputy Director at the State Key Laboratory of Low-Dimensional Quantum Physics (2011–2016)

  • Since 2018, he has been the Deputy Director of the Center for Nano-Optoelectronics at Tsinghua University.

📚 ACADEMIC CONTRIBUTIONS AND CITES

Prof. Xue's scholarly contributions include:

  • Over 160 peer-reviewed journal articles

  • Co-editorship of 3 specialized books

  • More than 15 granted patents, highlighting his commitment to innovation and practical applications of research.

His work is widely cited in the academic community, underscoring the impact of his discoveries and methodologies in optics and photonics.

🌏 IMPACT AND INFLUENCE

With a global academic footprint, including his tenure at MIT, Prof. Xue has cultivated strong international collaborations. He has mentored numerous students and young researchers, many of whom now hold prestigious academic and industry positions. His influence extends across disciplines, linking physics, materials science, engineering, and biomedical applications.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

As a seasoned physicist and an esteemed academic leader, Prof. Xue continues to inspire innovation in nano-optoelectronic technologies. His ongoing work at Tsinghua University's Center for Nano-Optoelectronics sets the stage for future breakthroughs in laser-based diagnostics, quantum optics, and nanomedicine.

Looking forward, his efforts are expected to contribute to the next generation of biomedical imaging tools and optical computing systems, playing a crucial role in shaping the future of quantum technologies and photonic engineering.

🔚 CONCLUSION

Prof. Ping Xue stands as a pillar in the fields of optics and nano-optoelectronics. His journey from a Tsinghua graduate to a global scientific influencer reflects a career of persistent innovation, deep theoretical insight, and practical breakthroughs. With over three decades of experience, a robust publication and patent record, and sustained leadership roles, his contributions will continue to inspire future generations of physicists and engineers in China and around the world.

📊🔬NOTABLE PUBLICATION:

1. Monte Carlo-based realistic simulation of optical coherence tomography angiography

Authors: Jianing Mao, Hang Su, Ping Xue, Yuye Ling

Journal: Biomedical Optics Express

Year: 2025

2. Importance sampling-accelerated simulation of full-spectrum backscattered diffuse reflectance

Authors: Jianing Mao, Yuye Ling, Ping Xue, Yikai Su

Journal: Biomedical Optics Express

Year: 2023

3. Monte Carlo-based full-wavelength simulator of Fourier-domain optical coherence tomography

Authors: Jianing Mao, Yuye Ling, Ping Xue, Yikai Su

Journal: Biomedical Optics Express

Year: 2022

4. Dispersion Measurement with Optical Computing Optical Coherence Tomography

Authors: Wenxin Zhang, Zhengyu Chen, Xiao Zhang, Chengming Wang, Bin He, Ning Liu, Yangkang Wu, Yuxiu Tao, Ning Zhang, Ping Xue

Journal: Photonics

Year: 2022

5. Theoretical and experimental study of hybrid optical computing engine for arbitrary-order FRFT

Authors: Jiaying Hong, Xi Zhou, Nian Xin, Zhengyu Chen, Bin He, Zhangwei Hu, Ning Zhang, Qin Li, Ping Xue, Xiao Zhang

Journal: Optics Express

Year: 2021​